ArticleClinical rheumatology2026
Complement activation and altered fibrin clot properties in obstetric antiphospholipid syndrome: impact on thromboembolism and pregnancy.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProthrombotic fibrin clot properties and increased thrombin generation were observed in obstetric antiphospholipid syndrome (OAPS), but the role of complement in the prothrombotic state is unclear.
objectivesThis study aimed to determine whether circulating C5a and C5b-9 levels are associated with fibrin clot phenotype and thrombin generation in women with OAPS, and to assess their prognostic value for thrombotic events and obstetric outcomes during long-term follow-up.
methodsIn this retrospective study, in 57 women with OAPS, and 57 controls matched for age, weight, and the type of obstetric complications complement components including C5a and C5b-9 levels, along with endogenous thrombin potential (ETP), plasma fibrin clot permeability (K
resultsOAPS patients compared to controls had higher circulating C5a (+ 95.7%) and C5b-9 (+ 44.8%; both p < 0.05), that were positively associated with IgG anticardiolipin, anti-ß-2-glycoprotein I, and antiphosphatidylserine/prothrombin antibodies. Elevated C5a and C5b-9 correlated with reduced clot permeability (K
conclusionDetermination of complement components along with fibrin clot properties may be helpful to differentiate women with OAPS with a greater risk of negative pregnancy outcomes. Key Points • Enhanced complement activation with increased thrombin generation and prothrombotic fibrin clot phenotype is observed in women with OAPS. • Higher C5a and C5b-9 in women with OAPS are observed in women with lower chances of live births during follow-up.
Indexed as
Identifiers
41507688What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.